IRVINE, Calif., Feb. 4, 2016 /PRNewswire/ -- Edwards
Lifesciences Corporation (NYSE: EW), the global leader in
patient-focused innovations for structural heart disease and
critical care monitoring, announced today that it has entered into
an accelerated share repurchase (ASR) agreement with Morgan Stanley
& Co. LLC to repurchase $325
million of Edwards' common stock. This repurchase is
part of the Company's previously authorized program to repurchase
up to $750 million of the Company's
common stock.
Under the terms of the ASR, Edwards has agreed to purchase
$325 million of its common stock from
Morgan Stanley & Co. LLC with an initial delivery of 3.2
million shares. The final number of shares repurchased and
delivered under the ASR will be based on the volume weighted
average share price of the Company's common stock over the ASR
period, which is expected to be up to ten months, subject to
certain adjustments pursuant to the ASR agreement. The
Company is funding the ASR with existing available cash.
About Edwards Lifesciences
Edwards Lifesciences, based in Irvine,
Calif., is the global medical technology leader in
patient-focused medical innovations for structural heart disease,
as well as critical care and surgical monitoring. Driven by a
passion to help patients, the company collaborates with the world's
leading clinicians and researchers to address unmet healthcare
needs, working to improve patient outcomes and enhance lives. For
more information, visit www.Edwards.com and follow us on Twitter at
@EdwardsLifesci.
Logo - http://photos.prnewswire.com/prnh/20140714/126903
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/edwards-lifesciences-announces-325-million-accelerated-share-repurchase-300215808.html
SOURCE Edwards Lifesciences Corporation